{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:00:53Z","timestamp":1787536853707,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82061128001"],"award-info":[{"award-number":["82061128001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bioorg.2025.108467","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:08:52Z","timestamp":1744369732000},"page":"108467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Synthesis and evaluation of novel amino pyrimidine derivatives containing sulfonamide and their application as EGFR inhibitors"],"prefix":"10.1016","volume":"160","author":[{"given":"Han","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longcai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puzhuang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingshu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108467_bb0005","article-title":"SEER cancer statistics review (CSR) 1975\u223c2017","author":"Howlader","year":"2020","journal-title":"National Cancer Institute."},{"key":"10.1016\/j.bioorg.2025.108467_bb0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.mam.2010.04.001","article-title":"Signal transduction therapy of cancer","volume":"31","author":"Levitzki","year":"2010","journal-title":"Mol. Asp. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108467_bb0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermalgrowth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108467_bb0020","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutationsin lung cancer: correlation with clinical response togefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.108467_bb0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non\u2212small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N. Engl. J.Med."},{"key":"10.1016\/j.bioorg.2025.108467_bb0030","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysisof tumor specimens at the time of acquired resistance to EGFR-TKITherapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin.Cancer. Res."},{"key":"10.1016\/j.bioorg.2025.108467_bb0035","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.2217\/fon.15.183","article-title":"Afatinib: a second-generation EGF receptor and ErbBtyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer","volume":"11","author":"Marquez-Medina","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.bioorg.2025.108467_bb0040","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-smallcell lung cancer","author":"J\u00a8anne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108467_bb0045","author":"The University of Arizona"},{"key":"10.1016\/j.bioorg.2025.108467_bb0050","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1158\/1078-0432.CCR-15-1915","article-title":"Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors","volume":"22","author":"Ortiz-Cuaran","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108467_bb0055","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2212 Pemetrexed in EGFRT790M\u2212 positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108467_bb0060","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1158\/1078-0432.CCR-15-1915","article-title":"Heterogeneous mechanisms ofPrimary and acquired resistance to third-generation EGFR inhibitors","volume":"22","author":"Ortiz-Cuaran","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108467_bb0065","doi-asserted-by":"crossref","first-page":"10272","DOI":"10.1021\/acs.jmedchem.9b01169","article-title":"Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors","volume":"62","author":"Engelhardt","year":"2019","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2025.108467_bb0070","doi-asserted-by":"crossref","first-page":"7302","DOI":"10.1021\/acs.jmedchem.9b00576","article-title":"Structure-based design of 5-Methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermalgrowth factor receptor triple mutant (EGFRL858R\/T790M\/C797S)","volume":"62","author":"Shen","year":"2019","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2025.108467_bb0075","doi-asserted-by":"crossref","first-page":"13704","DOI":"10.1021\/acs.jmedchem.1c01055","article-title":"Potent and selective inhibitors of the epidermal growth factor receptor to overcome C797S-mediated resistance","volume":"64","author":"Finlay","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108467_bb0080","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 overcomes Osimertinib-resistant EGFR-Del19\/T790M\/C797S mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108467_bb0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cas.15229","article-title":"LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo","volume":"113","author":"Liu","year":"2022","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108467_bb0090","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1021\/acs.jmedchem.2c00168","article-title":"Conformational constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine derivatives as new fourth-generation epidermal growthfactor receptor inhibitors targeting T790M\/C797S mutations","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108467_bb0095","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.1021\/acs.jmedchem.3c00277","article-title":"Discovery of potent and wild-type-sparing fourth generation EGFR inhibitors for treatment of Osimertinib-resistance NSCLC","volume":"66","author":"Dong","year":"2023","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108467_bb0100","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1021\/acs.jmedchem.3c00175","article-title":"Novel aryl sulfonamide derivatives as NLRP3 inflammasome inhibitors for the potential treatment of cancer","volume":"66","author":"Albanese","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108467_bb0105","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1016\/j.apsb.2023.01.003","article-title":"Discovery of novel sulfonamide substituted indolylarylsulfones as potent HIV-1 inhibitors with better safety profiles","volume":"13","author":"Gao","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108467_bb0110","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1021\/acs.jmedchem.1c00049","article-title":"Discovery of acyl-sulfonamide Nav1.7 inhibitors GDC-0276 and GDC-0310","volume":"64","author":"Safina","year":"2021","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108467_bb0115","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.2174\/1389557520666200905125738","article-title":"From antibacterial to antitumour agents: a brief review on the chemical and medicinal aspects of sulfonamides","volume":"20","author":"Azevedo-Barbosa","year":"2020","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108467_bb0120","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ejmech.2017.04.079","article-title":"J\u20acanne P a, Choi H G, gray N S","author":"Jang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2025.108467_bb0125","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1021\/jm400822z","article-title":"Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)","volume":"56","author":"Ward","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108467_bb0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejmech.2017.03.083","article-title":"Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC)","volume":"133","author":"Song","year":"2017","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825003475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825003475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:25:50Z","timestamp":1762223150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825003475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":26,"alternative-id":["S0045206825003475"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108467","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of novel amino pyrimidine derivatives containing sulfonamide and their application as EGFR inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108467"}}